arrow_rightarrow_righticon_excelicon_pficon_ppticon_wordmagnifier

Tuesday 16 May 2023

Tuesday 16 May

08:00

08:00 - 08:45 Sponsored breakfast meeting I

Please view more detailed information about this program item under the tab sponsored sessions.

08:00 - 08:45 [CLOSED meeting] SIOPEN Board meeting

08:00 - 08:45 Educational Session 1

08:00

Diagnostics and Staging in NB - assays, risk, current standard and new perspectives

Susan Cohn, United States

08:20

Neuroblastoma phenotypic states integrate multiple mutational and epigenetic changes

Frank Westermann, Germany

09:00 -10:00 Plenary session 3: Clinical trials and relapse treatment

Moderators: Yael Mossé, United States & Angelika Eggert, Germany

09:00

PS3.1 History of HR-NBL treatment

Julie Park, United States

09:15

PS3.2 SIOPEN-HR2: essentials of current high risk treatment protocol

Dominique Valteau, France

09:30

PS3.3 COG-ANBL1531: essentials of current high risk treatment protocol

Steve Dubois, United States

09:45

PS3.4 Relapse trials

Lucas Moreno, Spain

10:00

10:00 - 10:10 In Memoriam Audrey Evans

John Maris & Garrett Brodeur, United States

10:10

10:10 - 10:40 Coffee break

10:40 - 11:30 Parallel session 5: Metabolomics

Moderators: Murray Norris & Marie Arsenian Henriksson

10:40

O5.1 Maternal high fat diet accelerates neuroblastoma tumorigenesis

Belamy Cheung, Australia

10:52

O5.2 Ferroptosis, a novel liability of high-risk neuroblastoma

Karolina Garbowicz, Germany

11:04

O5.3 Reprogramming the neuroblastoma epigenome with mitochondrial uncoupler to promote differentiation therapy

Jiangbin Ye, United States

11:16

O5.4 Optimising polyamine inhibition therapy combined with standard-of-care chemotherapy and anti-GD2 immunotherapy through preclinical modelling in Th-MYCN mice

Jayne Murray, Australia

10:40 - 11:30 Parallel session 6: Clinical cohort studies

Moderators: Rochelle Bagatell, United States & Pat Reynolds, United States

10:40

O6.1 Growth retardation in long-term high-risk neuroblastoma survivors treated with high-dose chemotherapy

Dominique Valteau-Couanet, France

10:52

O6.2 High Risk Neuroblastoma (HR-NB) with MNA and age <18months: Results from the HR-NBL1/SIOPEN trial

Ruth Ladenstein, Austria

11:04

O6.3 Improved outcome for patients with alternative lengthening of telomeres (ALT) neuroblastoma randomized to tandem myeloablative therapy on COG ANBL0532

Patrick Reynolds, United States

11:16

O6.4 A Multicenter Cooperative Group Study of Survivors of High-Risk Neuroblastoma: The Late Effects after High-Risk Neuroblastoma (LEAHRN) Study (COG ALTE15N2)

Lisa Diller, United States

10:40 - 11:30 Parallel session 7: Genetic defects and dependencies in neuroblastoma

Moderators: Tao Liu, Australia & Michael Hogarty, United States

10:40

O7.1 SOX11 is a mediator of core regulatory circuit robustness: upregulation of SWI/SNF components and recruitment of transcriptional enhancer NONO

Amber Louwagie, Belgium

10:52

O7.2 Interplay between LDB1 and core transcription factors instructs enhancer-promoter interactions and determines cell-fate in neuroblastoma

Zhihui Liu, United States

11:04

Regulatory non-coding somatic mutations as drivers of neuroblastoma

Annalaura Montella, Italy

11:16

O7.4 Parallel sequencing of extrachromosomal circular DNA and mRNA in single neuroblastoma cells

Maria Del Rocio Chamorro Gonzalez, Germany

11:30

11:30 - 13:30 [CLOSED MEETING] Parents Organizations

11:30 -11:45 Rapid Fire session 1B

Moderator: Bram de Wilde, Belgium

11:31

P127 Exploring the role of MYCN in the mitochondria to discover MYCN-Amplified tumour vulnerabilities

Soraya Epp, Ireland

11:32

P126 CDK12 as a target for combinatorial drugging of high-risk neuroblastoma

Joshua Robert Goulding, Belgium

11:33

P131 Joint inhibition of oncogenic and epigenetic targets PPM1D and KDM6B synergistically suppresses neuroblastoma growth

Diana Treis, Sweden

11:34

P125 Drug repurposing for high-risk neuroblastoma

Katarzyna Radke, Sweden

11:35

P076 Atypical neuroblastoma: screening of urinary catecholamine excretion and mIBG avidity at diagnosis, a retrospective study

Anna Borovkov, France

11:36

P077 Cause and consequence of intra- and inter-tumor heterogeneity in zebrafish models of neuroblastoma

Nora Fresmann, Germany

11:37

P296 Long-term Follow-up of the Children’s Oncology Group (COG) Intermediate-risk Phase III ANBL0531 Study Using Response- and Biology-Based Therapy

Erin Barr, United States

11:38

P297 Predictors of Differential Outcomes According to Response to Induction Chemotherapy in High-Risk Neuroblastoma 

Elizabeth Sokol, United States

11:39

P271 Persistence of Racial and Ethnic Disparities in Risk and Survival for Patients with Neuroblastoma: An International Neuroblastoma Risk Group Project

Mohansrinivas Chennakesavalu, United States

11:40

P298 Response-Adapted Consolidation Therapy Strategy for Patients With Metastatic High-Risk Neuroblastoma: Results From the SMC NB-2014 Study

Eun Seop Seo, South Korea

11:45

11:45 - 12:45 Lunch + Poster Session group B

Poster viewing: P001-P191 - Poster Session Group B: P111 until P191

12:00

12:00 - 13:00 [CLOSED MEETING] ANRA Advisory Board Meeting

13:45 - 14:30 Keynote Lecture 2

Moderator: Max van Noesel, the Netherlands

13:45

Drug development in Pediatric Oncology

Michel Zwaan, the Netherlands

14:30 - 15:30 Plenary session 4: Precision therapy

Moderators: Michelle Haber, Australia & Louis Chesler, UK

14:30

PS4.1 Phase 2 trial of the Wee1 inhibitor Adavosertib and Irinotecan in Neuroblastoma

Kristina Cole, United States

14:45

PS4.2 Mutated fibroblast growth factor receptor 1 is a strong oncogenic driver and a therapeutic target in neuroblastoma

Lisa Werr, Germany

15:00

PS4.3 Combined targeting of metabolic dependencies of proline translation in neuroblastoma

Raphael Johannes Morscher, Switzerland

15:15

PS4.4 Low GD2 expression as a mechanism of resistance to chemoimmunotherapy with dinutuximab

Michelle Keyel, United States

15:30

15:30 - 16:00 Coffee break

16:00 - 16:50 Parallel session 8: Precision therapy: Novel targets

Moderators: Rani George, United States & Anton Henssen, Germany

16:00

O8.1 Drug sensitivity profiling of 3D neuroblastoma cultures in the pediatric precision oncology program INFORM

Ina Oehme, Germany

16:12

O8.2 Interactive online repository demonstrating drug sensitivity associated with genomic and transcriptomic profiles of patient-derived neuroblastoma organoids and classical cell lines

Karin Langenberg, the Netherlands

16:24

O8.3 Drugging the ATR-CHK1-RRM2 replicative stress signalling axis in neuroblastoma: exploring deeper mechanistic insights and novel drugging options

Iris Nelen, Belgium

16:36

O8.4 Nanoarchitectonics of the M13 phage provides a potent and specific anti-GD2 vector platform for Neuroblastoma Therapy

Suleman Khan Zadran, Italy

16:00 - 16:50 Parallel session 9: Plasticity in neuroblastoma and normal development

Moderators: Adam Durbin, United States & Isabelle Janoueix, France

16:00

O9.1 Single-nuclei transcriptomes from human adrenal gland reveals distinct cellular identities of low and high-risk neuroblastoma tumors

Oscar Bedoya, Sweden

16:12

O9.2 Trunk neural crest enriched MOXD1 suppresses tumor growth in neuroblastoma

Elina Fredlund, Sweden

16:24

O9.3 A harmonized single-cell transcriptomic atlas of human neuroblastoma

Noah Bonine, Belgium

16:36

O9.4 Single-cell profiling of the neuroblastoma heterogeneity at the bone marrow metastatic niche

Magdalena Rados, Osterreich

16:00 - 16:50 Parallel session 10: Tumor-micro environment interactions

Moderators: Yves Declerck, United States & Sabine Taschner-Mandl, Austria

16:00

O10.1 Single-cell transcriptomics and epigenomics unravel the role of monocytes at the bone marrow metastatic niche in neuroblastoma

Irfete Fetahu, Austria

16:12

O10.2 Cancer-associated fibroblasts drive mesenchymal transition and therapeutic resistance via TGFb/NFkB signaling in neuroblastoma

Kevin Louault, United States

16:24

O10.3 Changes in the bone marrow microenvironment upon neuroblastoma metastasis

Ilse Timmerman, the Netherlands

16:36

O10.4 Macrophage infiltration promotes regrowth in MYCN amplified neuroblastoma after chemotherapy

Catharina Hagerling, Sweden

16:50

Poster session group B

Posters with reference P111 until P191

17:30

17:30 - 19:00 Young Investigator Reception

Dinner on your own